• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Two-pronged atorvastatin administration for prophylaxis of acute GVHD

byAndrew Bishara
November 2, 2013
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Atorvastatin administration for both healthy donors and recipients of matched sibling allogeneic hematopoietic cell transplantation (HCT) represents feasible and safe potential acute GVHD prophylaxis.

2. Further investigation is needed to determine the effectiveness of this strategy.

Evidence rating level: 2 (Good) 

Study Rundown: Acute graft-versus-host disease (GVHD) causes significant morbidity and mortality following allogeneic hematopoietic cell transplantation, occurring in up to 50% of patients receiving HLA-matched transplants. Current prophylaxis has only modest efficacy and may compromise donor T cell-mediated graft-versus-host effects and delay immune reconstitution. Studies with murine models have suggest that two-pronged atorvastatin therapy for both donors and recipients has synergistically protective effects against acute GVHD compared to donor or recipient treatment alone. Therefore, the purpose of this study was to evaluate the safety and feasibility of this approach.

The authors found that this two-pronged approach was not associated with significant toxicities or primary treatment failures. Furthermore, adherence to the regimen was strong, suggesting that this treatment could feasibly be applied in a clinical setting. Nevertheless, it should be noted that this phase II trial had a small sample size and lacked a control arm with which to compare the efficacy of this treatment. Further trials are required to evaluate the benefit, if any, this approach offers to these patients.

RELATED REPORTS

#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

Incyte and Syndax: Niktimvo led to significant disease response rates in patients with recurrent chronic graft-versus-host-disease (cGVHD).

Click to read the article in JCO

Relevant reading: Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoetic cell transplantation

In-Depth [phase II prospective cohort study]: For this prospective trial, the study authors enrolled patients with hematologic malignancies and HLA-matched adult sibling donors. Patients and donors with active infections, abnormal renal, hepatic, pulmonary or cardiac function, poor Karnofsky performance scores and history of atorvastatin intolerance or allergy were excluded. For acute GVHD prophylaxis arm, donors were given atorvastatin for at least 14 days. All patients received uniform GVHD prophylaxis with tacrolimus, methotrexate, and atorvastatin.  The primary end points were donor/patient safety and cumulative incidence of grade 2 to 4 acute GVHD at day +100. Secondary end points included cumulative incidence of grade 3 to 4 acute GVHD, chronic GVHD, disease relapse, nonrelapse mortality, progression-free survival and overall survival.

Though atorvastatin administration to both donors and recipients was not associated with grade 3 to 4 GVHD, cumulative incidence of grades 2 to 4 at days +100 and +180 were 3.3% (CI, 0.2%-14.8%) and 11.1% (CI, 2.7% to 26.4%). One year cumulative incidence of chronic GVHD was 52.3% (ci, 27.6% TO 72.1%). One-year cumulative incidence of nonrelapse mortality and relapse were 9.8% (CI, 1.4% to 28%) and 25.4% (10.9% to 42.9%). One year overall survival and progression-free survival were 74% (CI, 58% to 96%) and 65% (CI, 48% to 87%). Viral and fungal infections were uncommon.

By Monica Parks and Andrew Bishara

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Atorvastatingvhdhematopoietic cell transplantationmethotrexatephase II prospective cohort studytacrolimus
Previous Post

Spontaneous early term delivery associated with subsequent preterm birth

Next Post

2 Minute Medicine Rewind October 28 – November 3, 2013

RelatedReports

#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis
StudyGraphics

#VisualAbstract: Methotrexate is Noninferior to Prednisone in the Treatment of Pulmonary Sarcoidosis

May 30, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

October 30, 2024
Age and number of islet autoantibodies associated with diabetes risk
Pharma

Incyte and Syndax: Niktimvo led to significant disease response rates in patients with recurrent chronic graft-versus-host-disease (cGVHD).

September 12, 2024
#VisualAbstract: Methotrexate alleviates pain among patients with hand osteoarthritis and concurrent synovitis
StudyGraphics

#VisualAbstract: Methotrexate alleviates pain among patients with hand osteoarthritis and concurrent synovitis

December 13, 2023
Next Post
Patient transfers to trauma centers often unnecessary

2 Minute Medicine Rewind October 28 - November 3, 2013

Undervaccination becoming more common, associated with increased patient admission rates

Shared decision-making associated with increased parental resistance to vaccinations

Tenofovir-emtricitabine more effective and safer than zidovudine-lamivudine in HIV treatment [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.